Descrizione del progetto
Uno strumento predittivo innovativo per garantire l’efficacia degli antidepressivi
Il disturbo depressivo maggiore colpisce 280 milioni di persone nel mondo. Per trattarlo esistono numerosi antidepressivi, ma pochissimi pazienti (meno del 6 %) traggono benefici dai metodi terapeutici. Il progetto OPADE, finanziato dall’UE, identificherà i biomarcatori fondamentali che aiutano il processo decisionale degli operatori sanitari, concentrando l’attenzione sull’asse microbiota-cervello, che svolge un ruolo centrale nella salute mentale e nel disturbo depressivo maggiore. Studiando la genetica, l’epigenetica, i microbiomi e le reti infiammatorie per determinare i profili dei pazienti, il progetto prevederà e ottimizzerà l’efficacia degli antidepressivi. Inoltre, indagherà la possibile correlazione tra gli indici neuroinfiammatori, gli indicatori bersaglio del microbioma, la metabolomica, la profilazione immunitaria e gli algoritmi epigenomici ed enzimatici. Il progetto userà i risultati e le analisi ottenuti per addestrare l’intelligenza artificiale e uno strumento predittivo a base di apprendimento automatico.
Obiettivo
280M of people worldwide suffers from major depressive disorders (MDD). Although a well-populated therapeutic landscape of anti-depre280M of people worldwide suffers from major depressive disorders (MDD). Although a well-populated therapeutic landscape of anti-depressants, the number of patients in remission is particularly low with not more than 6% of the patients who benefit from the current therapeutic journey.
OPADE objective is to identify key biomarkers that support the decision-making process of the healthcare providers.
The project focuses on the microbiota – brain -axis which plays a major role in mental health and in particular MDD. Through clinical investigations, the consortium partners will study the combination between genetics, epigenetics, microbiome and inflammatory networks to:
- Establish patient profiles to predict and optimise the efficacy of the antidepressants prescribed with an increase in the remission rate and reduction of impairment of real-life functioning,
- Establish the possible correlation between neuroinflammatory indices, target indicators of the microbiome, metabolomics, immune-profile linked, epigenomic, enzymatic algorithms,
- Evaluate molecular and non-molecular biomarkers that may represent predictive indices of recurrence
- Discover new molecular targets for a personalised approach,
- Improve the diagnostic accuracy for primary prevention,
- Evaluate retrospectively, using accurate anamnesis, the onset of depressive symptoms in adolescence.
- Establish how much and to what extent do blood biomarkers correlate with other specific biomarkers
350 patients between 14 and 50 years will be recruited in 6 EU and international countries for 24 months. Real-time EEG and patient cognitive assessment will be collected with blood, stool and saliva samples. Results and analysis will be used to train the AI / ML predictive tool, the main outcome of the project. A patient empowerment tool will be deployed over the project duration.
Campo scientifico
Programma(i)
Meccanismo di finanziamento
HORIZON-RIA - HORIZON Research and Innovation ActionsCoordinatore
84125 Salerno
Italia